Updating results

180 results for Copyright

Sort: Relevance | Date

Minocycline (KTT11)

statement . Copyright © National Institute for Health and Care Excellence, 2015. All rights reserved. NICE copyright...

Key therapeutic topic Published January 2015

Laxatives (KTT1)

statement . Copyright © National Institute for Health and Care Excellence, 2015. All rights reserved. NICE copyright...

Key therapeutic topic Published January 2015

Renin-angiotensin system drugs: dual therapy (KTT2)

statement . Copyright © National Institute for Health and Care Excellence, 2016. All rights reserved. NICE copyright...

Key therapeutic topic Published January 2015 Last updated February 2016

First-choice antidepressant use in adults with depression or generalised anxiety disorder (KTT8)

statement . Copyright © National Institute for Health and Care Excellence, 2016. All rights reserved. NICE copyright...

Key therapeutic topic Published January 2015 Last updated February 2016

Clostridium difficile infection: fidaxomicin (ESNM1)

Summary of the evidence on fidaxomicin for treating Clostridium difficile (C. diff/C. difficile) infection to inform local NHS planning and decision-making

Evidence summary Published July 2012

QTUG for assessing falls risk and frailty (MIB73)

Advice on the use of the Quantitative Timed Up and Go (QTUG) to assess mobility, falls risk and frailty during the standard Timed Up and Go (TUG) test to aid…

Medtech innovation briefing Published July 2016

Stretta System for gastro-oesophageal reflux disease (MIB74)

Advice on the use of Stretta System for gastro-oesophageal reflux disease (GORD)

Medtech innovation briefing Published July 2016

Chronic obstructive pulmonary disease: glycopyrronium bromide (ESNM9)

Summary of the evidence on glycopyrronium bromide for treating chronic obstructive pulmonary disease (COPD) to inform local NHS planning and decision-making

Evidence summary Published January 2013

Actinic keratosis: ingenol mebutate gel (ESNM14)

Summary of the evidence on ingenol mebutate gel for actinic keratosis (solar keratosis) to inform local NHS planning and decision-making

Evidence summary Published March 2013

Asthma: fluticasone/formoterol (Flutiform) combination inhaler (ESNM3)

Summary of the evidence on fluticasone/formoterol (Flutiform) combination inhaler for treating asthma to inform local NHS planning and decision-making

Evidence summary Published October 2012

Partial-onset seizures in epilepsy: perampanel as adjunctive treatment (ESNM7)

Summary of the evidence on perampanel for partial-onset seizures in epilepsy (in people aged 12 and over) to inform local NHS planning and decision-making

Evidence summary Published December 2012

Partial-onset seizures in epilepsy: zonisamide as monotherapy (ESNM17)

Summary of the evidence on zonisamide as monotherapy for children and young people with epilepsy to inform local NHS planning and decision-making

Evidence summary Published April 2013

Acute diarrhoea in adults: racecadotril (ESNM11)

Summary of the evidence on racecadotril for treating acute diarrhoea in adults to inform local NHS planning and decision-making

Evidence summary Published March 2013

Chronic obstructive pulmonary disease: aclidinium bromide (ESNM8)

Summary of the evidence on aclidinium bromide for treating chronic obstructive pulmonary disease (COPD) to inform local NHS planning and decision-making

Evidence summary Published January 2013

Acute diarrhoea in children: racecadotril as an adjunct to oral rehydration (ESNM12)

Summary of the evidence on racecadotril with oral rehydration for treating acute diarrhoea in children to inform local NHS planning and decision-making

Evidence summary Published March 2013

The PolySoft hernia patch used with the ONSTEP technique to treat inguinal hernias (MIB9)

Advice on the use of the PolySoft hernia patch with the ONSTEP technique for treating inguinal hernias to aid local decision-making

Medtech innovation briefing Published August 2014

Irritable bowel syndrome with constipation in adults: linaclotide (ESNM16)

Summary of the evidence on linaclotide for irritable bowel syndrome (IBS) with constipation in adults to inform local NHS planning and decision-making

Evidence summary Published April 2013

Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)

Summary of the evidence on subcutaneous trastuzumab for HER2-positive breast cancer to inform local NHS planning and decision-making

Evidence summary Published March 2013

Secca System for faecal incontinence (MIB66)

Advice on the use of the Secca system for treating faecal incontinence to aid local decision-making

Medtech innovation briefing Published May 2016

AccuVein AV400 for vein visualisation (MIB6)

Advice on the use of AccuVein AV400 for vein visualisation (peripheral venous access) to aid local decision-making

Medtech innovation briefing Published June 2014

Asthma: beclometasone/formoterol (Fostair) for maintenance and reliever treatment (ESNM22)

Summary of the evidence on beclometasone/formoterol (Fostair) for treating asthma to inform local NHS planning and decision-making

Evidence summary Published June 2013

Chronic obstructive pulmonary disease: fluticasone furoate plus vilanterol (ESNM21)

Summary of the evidence on fluticasone furoate plus vilanterol for treating chronic obstructive pulmonary disease (COPD)..

Evidence summary Published June 2013

Attention deficit hyperactivity disorder in children and young people: lisdexamfetamine dimesylate (ESNM19)

Summary of the evidence on lisdexamfetamine dimesylate for attention defecit hyperactivity disorder (ADHD) in children and young people..

Evidence summary Published May 2013

Prostate cancer: triptorelin (Decapeptyl SR) (ESNM30)

Summary of the evidence on triptorelin (Decapeptyl SR) for treating prostate cancer to inform local NHS planning and decision-making

Evidence summary Published January 2014

Symptoms of peripheral arterial disease: ramipril (ESUOM45)

Summary of the evidence on ramipril for relieving the symptoms of peripheral arterial disease (PAD) to inform local NHS planning and decision-making

Evidence summary Published June 2015

The Versajet II hydrosurgery system for surgical debridement of acute and chronic wounds and burns (MIB1)

Advice on the use of the Versajet II hydrosurgery system for surgical debridement of acute and chronic wounds and burns to aid local decision-making

Medtech innovation briefing Published February 2014

The OSCAR 3 ultrasonic arthroplasty revision instrument for removing bone cement during prosthetic joint revision (MIB13)

Advice on the use of the OSCAR 3 ultrasonic arthroplasty revision instrument for removing bone cement during prosthetic joint revision..

Medtech innovation briefing Published November 2014

Episcissors-60 for guided mediolateral episiotomy (MIB33)

Advice on the use of the Episcissors-60 for guided mediolateral episiotomy to aid local decision-making

Medtech innovation briefing Published July 2015

Induction of labour: misoprostol vaginal delivery system (ESNM38)

Summary of the evidence on the misoprostol vaginal delivery system for induction of labour to inform local NHS planning and decision-making

Evidence summary Published March 2014 Last updated November 2014

Gouty arthritis: canakinumab (ESNM23)

Summary of the evidence on canakinumab for treating gouty arthritis (gout) to inform local NHS planning and decision-making

Evidence summary Published July 2013

ClearWay RX for drug delivery to coronary artery thrombotic lesions (MIB55)

Advice ClearWay RX for drug delivery to coronary artery thrombotic lesions to aid local decision-making

Medtech innovation briefing Published March 2016

Chronic urticaria: off-label doses of cetirizine (ESUOM31)

Summary of the evidence on off-label doses of cetirizine for chronic urticaria (hives) to inform local NHS planning and decision-making

Evidence summary Published July 2014

External genital and perianal warts: green tea (Camellia sinensis) leaf extract 10% ointment (ESNM66)

Summary of the evidence on green tea (Camellia sinensis) leaf extract 10% ointment for treating external genital and perianal warts to inform local NHS planning

Evidence summary Published December 2015

The Epidrum for aiding access to the epidural space (MIB23)

Advice on the use of the Epidrum for aiding access to the epidural space to aid local decision-making

Medtech innovation briefing Published March 2015

Hypersexuality: fluoxetine (ESUOM46)

Summary of the evidence on fluoxetine for treating hypersexuality to inform local NHS planning and decision-making

Evidence summary Published July 2015

Cystic fibrosis: long-term azithromycin (ESUOM37)

Summary of the evidence on long-term azithromycinoral for treating cystic fibrosis (CF) to inform local NHS planning and decision-making

Evidence summary Published November 2014

Spiral Flow peripheral vascular graft for treating peripheral arterial disease (MIB34)

Advice on the use of the Spiral Flow peripheral vascular (PV) graft for treating peripheral arterial disease (PAD) to aid local decision-making

Medtech innovation briefing Published July 2015

Long-acting reversible contraception: levonorgestrel 13.5 mg intrauterine delivery system (ESNM41)

Summary of the evidence on the levonorgestrel intrauterine delivery system (long-acting reversible contraception) to inform local NHS planning...

Evidence summary Published June 2014

Erectile dysfunction: Alprostadil cream (ESNM50)

Summary of the evidence on alprostadil cream for treating erectile dysfunction to inform local NHS planning and decision-making

Evidence summary Published December 2014

Combined oral contraception: nomegestrol/estradiol (Zoely) (ESNM28)

Summary of the evidence on nomegestrol/estradiol (Zoely) for use as combined oral contraception to inform local NHS planning and decision-making

Evidence summary Published December 2013

Lower urinary tract symptoms secondary to benign prostatic hyperplasia: tadalafil (ESNM18)

Summary of the evidence on tadalafil for lower urinary tract symptoms secondary to benign prostate hyperplasia..

Evidence summary Published May 2013 Last updated October 2013

Schizophrenia: aripiprazole prolonged-release suspension for injection (ESNM39)

Summary of the evidence on aripiprazole prolonged-release suspension for injection for schizophrenia to inform local NHS planning and decision-making

Evidence summary Published March 2014

LATITUDE NXT Patient Management System for monitoring cardiac devices at home (MIB67)

Advice on the use of the LATITUDE NXT Patient Management System for monitoring cardiac devices to aid local decision-making

Medtech innovation briefing Published May 2016

Management of vomiting in children and young people with gastroenteritis: ondansetron (ESUOM34)

Summary of the evidence on ondansetron for the management of vomiting in children and young people with acute gastroenteritis...

Evidence summary Published October 2014

Asthma: tiotropium (Spiriva Respimat) (ESNM55)

Summary of the evidence on tiotropium (Spiriva Respimat) for treating asthma to inform local NHS planning and decision-making

Evidence summary Published March 2015

Long-acting reversible contraception: subcutaneous depot medroxyprogesterone acetate (DMPA‑SC) (ESNM31)

Summary of the evidence on subcutaneous depot medroxyprogesterone acetate (DMPA-SC) for long-acting reversible contraception..

Evidence summary Published January 2014

Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)

Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making

Evidence summary Published June 2015

Digital ulcers: sildenafil (ESUOM42)

Summary of the evidence on sildenafil for managing digital ulcers to inform local NHS planning and decision-making

Evidence summary Published March 2015

Hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus: telavancin (ESNM44)

Summary of the evidence on telavancin (Vibativ) for hospital-acquired pneumonia caused by MRSA to inform local NHS planning and decision-making

Evidence summary Published July 2014

Management of aggression, agitation and behavioural disturbances in dementia: carbamazepine (ESUOM40)

Summary of the evidence on carbamazepine for managing aggression, agitation and behavioural disturbances in people with dementia..

Evidence summary Published March 2015